RE:ViaCyte Diabetic research is being conducted all over the world.
Not only Viacyte, but also many other companies, such as InnoCann Pharma (a small Israeli company, which is also traded on the stock exchange in Canada) are very active in this field and report successes that are very promising:
Herzliya (Israel) and Calgary (Alberta), July 9, 2021. Innocan Pharma Corporation (CSE: INNO, FWB: IP4, OTC: INNPF) ("Innocan" or the "Company") announces the filing of an international patent application for a topical compound for the treatment of diabetes symptoms. The patent application covers and claims several preparations for topical administration containing a cannabinoid for the treatment of diabetes disorders. Specifically, the preparations enable the improvement of blood flow to peripheral areas in patients suffering from diabetes symptoms.
Diabetes is a chronic metabolic disease characterized by elevated blood sugar levels, which over time leads to severe damage to the heart, blood vessels, eyes, kidneys and nerves.
According to the CDC (Centers for Disease Control and Prevention, 2020), 463 million adults worldwide suffer from diabetes. In the U.S. alone, 34.2 million adults have been diagnosed with diabetes - 10.5% of the population.
Innocan is expanding its intellectual property portfolio of cannabis-based products to be a source of potential breakthroughs in skin therapy, as well as other opportunities in the comprehensive spectrum of indications in inflammation with currently unmet medical needs.
"Diabetes is considered one of the great diseases of the 21st century," said CEO Iris Bincovich. "As caloric intake increases, more and more people are suffering from various syndromes associated with severe diabetes, such as ulcers and foot disease, which can lead to death. Our IP portfolio continues to expand, which we believe positions Innocan as a significant player in this space." Bincovich continued, "I am pleased to report that this is our 12th patent for Innocan, and we are working hard to file additional patents soon."
Of course, they are different products.
But it shows that I think it's just a matter of time,
before new products enter the market.